ArticleFrontiers in psychiatry2020
National Prescription Patterns of Antidepressants in the Treatment of Adults With Major Depression in the US Between 1996 and 2015: A Population Representative Survey Based Analysis.
Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 104 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 6 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- Association between antidepressant use and gynecological cancer risk: a systematic review and meta-analysis.European journal of clinical pharmacology · 2025Pooled it
- Beneficial and harmful effects of tricyclic antidepressants for adults with major depressive disorder: a systematic review with meta-analysis and trial sequential analysis.BMJ mental health · 2024Pooled it
- Risk of Gastrointestinal Bleeding with Concurrent Use of NSAID and SSRI: A Systematic Review and Network Meta-Analysis.Digestive diseases and sciences · 2023Pooled it
- Neural correlates of psychodynamic and non-psychodynamic therapies in different clinical populations through fMRI: A meta-analysis and systematic review.Frontiers in human neuroscience · 2022Pooled it
- The incidence risk of breast and gynecological cancer by antidepressant use: A systematic review and dose-response meta-analysis of epidemiological studies involving 160,727 patients.Frontiers in oncology · 2022Pooled it
- Association of Single-blind Placebo Run-in Periods With the Placebo Response in Randomized Clinical Trials of Antidepressants: A Systematic Review and Meta-analysis.JAMA psychiatry · 2022Pooled it
- Investigating the relationship between hippocampus/dentate gyrus volume and hypothalamus metabolism in participants with major depressive disorder.Scientific reports · 2024Trial
- Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Efficacy and safety of zuranolone co-initiated with an antidepressant in adults with major depressive disorder: results from the phase 3 CORAL study.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Trial
- Effects of SSRIs on the spatial transcriptome of dorsal raphe serotonin neurons.Molecular psychiatry · 2026Article
- The Relationship Between Selective Serotonin Reuptake Inhibitor Use and Delayed Bleeding After Colorectal Endoscopic Resection: A Nationwide Retrospective Cohort Study.Digestive diseases and sciences · 2026Article
- Understanding antidepressant change patterns in the UK Biobank.The British journal of psychiatry : the journal of mental science · 2026Article
- Primary adherence to medications for the treatment of major depressive disorder: A descriptive study using real-world data.Journal of managed care & specialty pharmacy · 2026Article
- Intranasal 5-MeO-DMT Concomitant with SSRI for Treatment-Resistant Depression: A Proof-of-Concept Trial.CNS drugs · 2026Article
- Mapping the reciprocal interactions between antidepressants and the gut microbiome: novel targets for the personalisation and optimization of drug response.Molecular psychiatry · 2026Review
- Deep learning using electroencephalogram (EEG) data for diagnosing and predicting SSRI response in major depressive disorder.Communications medicine · 2026Article
- Exploring Molecular Mechanism of Fluoxetine in Animal Models of Depression via Integrated Metabolomic and Proteomic Analysis.Journal of cellular and molecular medicine · 2026Article
- The evolution of SSRI research: trajectories of knowledge domains across four decades.BMC psychiatry · 2026Article
- Diagnosis of depression in adolescence signals improved inflammatory health in adulthood: Results from a nationally representative longitudinal study.Brain, behavior, and immunity · 2026Article
- Influence ofPharmaceuticals (Basel, Switzerland) · 2026Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
5 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Few studies have delineated the real-world, long-term trends of prescription patterns of antidepressants for patients with major depressive disorder (MDD). This study aims to describe their vicissitudes in the nationally representative sample of the US from 1996 to 2015 and explore their characteristics. We used the Medical Expenditure Panel Survey, a nationally representative database of the US population, between 1996 and 2015. We estimated the prevalence of MDD among adults, calculated the proportions of those on antidepressant treatment as well as those on specific drugs through the two decades, and determined their dosages in 2015. We conducted multivariable regression to find possible factors related to their suboptimal prescriptions. The prevalence of adults diagnosed with MDD increased from 6.1% (95% CI, 5.7-6.6%) in 1996 to 10.4% (9.7-11.1%) in 2015. The proportion of patients without any antidepressant therapy decreased but still accounted for 30.6% (28.3-33.1%) in 2015. Sertraline and fluoxetine were among the most frequently prescribed antidepressants throughout the 20 years, while the trend for some new drugs changed dramatically. 16.1% (12.5-20.2%) of patients of MDD on antidepressant monotherapy were prescribed with suboptimal doses in 2015; the risk was lower for those who had higher Body Mass Index (OR 0.94 [0.90-0.99]), longer-term prescriptions (OR 0.92 [0.87-0.97]), and the risk was higher for those who were prescribed with tricyclic antidepressants (OR 11.21 [2.12-59.34], compared with serotonin reuptake inhibitors (SSRIs)), and antidepressants other than SSRIs and serotonin and norepinephrine reuptake inhibitors (OR 4.12 [1.95, 8.73], compared with SSRIs). This study confirmed the growing numbers of patients with MDD and the increase in the antidepressant prescriptions among them. However, the existence of patients without any antidepressant prescriptions or with suboptimal prescriptions and the variable prescription patterns through the decades might suggest some unresolved gaps between evidence and practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.